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Abstract
Introduction. Prediction of response to preoperative breast cancer chemotherapy may offer a substantial opti-
mization of medical management of this disease. The most efficient prediction would be done a priori, before 
the start of chemotherapy and based on the biological features of patient and tumor. Numerous markers have 
been proposed but none of them has been applied as a routine. The role of MKI67 and HSP90 expression has 
been recently suggested to predict treatment sensitivity in HER2-positive breast cancer. The aim of this study 
was to validate the utility of proliferation based markers (MKI67 and CDK1) and heat shock proteins (namely 
HSP90) to predict response to chemotherapy in cohort of breast cancer patients treated preoperatively. 
Material and methods. Ninety-three patients with breast cancer, all females, mean age 42.2 years, among them 
32% T1-T2 patients, 49% T3 patients and 13% with T4 tumor stage, 27% N0, 42% N1, 16% N2, 15% N3 were 
subjected to initial chemotherapy. The majority of patients (86%) received anthracycline and taxane chemo-
therapy. Among the patients there were 9 individuals with metastatic disease (M1) at initial presentation, and 
11 patients were not treated surgically after initial chemotherapy (no sufficient disease response). From 82 patients 
operated on, 20 patients (24%) showed pathological complete response (pCR), while in 62 patients there was 
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no pCR. 42% of patients were hormone-sensitive HER2-negative, 20% hormone-sensitive HER2-positive, 
9% only HER-positive and 29% with triple negative breast cancer. 
Four gene transcripts (MKI67, cyclin-dependent kinase 1 [CDK1], heat shock proteins HSP90AA1 and HSP-
90AB1) were analyzed in total RNA isolated from single core obtained during preoperative core needle biopsy by 
quantitative real-time PCR with fluorescent probes (Universal Probe Library, Roche). Results were normalized 
to the panel of reference genes. 
Results. There were no statistically significant differences in MKI67 and CDK1 expression between pCR and no 
pCR groups (p = 0.099 and 0.35, respectively), although the median expression of both genes was slightly higher 
in pCR group. In contrast, both HSP90AA1 and HSP90AB1 transcripts showed decreased expression in pCR 
group (medians 0.77 and 0.55) when compared to no pCR group (median 0.86 and 0.73), statistically significant 
for HSP90AA1 (p = 0.031) and of borderline significance for HSP90AB1 (p = 0.054).
The most significant predictor of pCR was the ratio of CDK1 transcript to HSP90AA transcript. This ratio 
was significantly higher in CR group (median 0.99) than in no CR group (median 0.68, p = 0.0023), and 
showed a potential diagnostic utility (area under receiver operating characteristic [ROC] curve 0.72).
Conclusions. HSP90AA1 and AB1 genes exhibit low expression in breast cancers highly sensitive to chemo-
therapy and may indicate the patients with higher probability of pathological complete response. The ratio of 
HSP90AA1 to proliferation-related markers (CDK1 or MKI67) may be even better predictor of pCR chance, 
with higher expression of proliferation genes and lower stress response in patients sensitive to chemotherapy. 
(Folia Histochemica et Cytobiologica 2016, Vol. 54, No. 4, 202–209)
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Introduction
Prediction of response to preoperative breast cancer 
chemotherapy may offer a substantial optimization 
of medical management of this disease. The most 
efficient prediction would be done a priori, before 
the start of chemotherapy and would be based on 
the biological features of patient and tumor. This 
approach allows for the selection of patients who 
may benefit from therapy and may aid the choice of 
treatment regimen. The alternative approach is the 
prediction made after the therapy has been initiated, 
either based on the treatment response visualization 
by imaging studies or by the change of biomarkers 
representing the disease burden (the latter currently 
less developed, e.g. serum markers).
The idea of a priori prediction has been evaluated 
in many studies; however, no efficient markers have 
been found and the research slowed down after the 
broad acceptance of heterogeneity of breast cancer 
molecular subtypes. These subtypes are applied as 
a surrogate tool to select patients with chemosensitive 
disease. Although the subtypes show clearly different 
biological features, cytotoxic chemotherapy remains 
the mainstay of treatment in luminal B, HER2-posi-
tive and triple negative breast cancer. As novel drugs 
appear (often less toxic than cytostatics), the impor-
tance of selection of patients who may benefit from 
chemotherapy is growing. 
There are many reports suggesting the importance 
of markers of proliferation, especially the most clinically 
widespread assessment of MKI67 gene expression, for 
the chemotherapy response (e.g. Nishimura et al. [1]). 
Recently, the role of this proliferation-related protein 
in context of the expression of (among others) heat 
shock protein HSP90 has been suggested by Bria et al. [2] 
to predict treatment sensitivity in HER2-positive 
breast cancer, when chemotherapy was combined 
with targeted anti-HER2 treatment. This focused our 
attention, as previously these two important features 
of cancer cell (proliferation and shock response) were 
not related to each other in the context of chemo-
therapy response prediction in breast cancer. Thus, 
we undertook the study aiming to assess the utility of 
proliferation based markers (MKI67 and CDK1) and 
heat shock proteins (namely HSP90) to predict the 
response to breast cancer preoperative chemotherapy. 
Material and methods 
Ninety-three patients with breast cancer, all females, mean 
age 42.2 years (95% confidence interval 40.5–43.9 years, 
median 41 years) were enrolled to the study. Patients were 
selected before the preoperative chemotherapy, either due 
to locally advanced or oligometastatic breast cancer or 
early-stage disease with intent of breast-conserving surgery 
after neoadjuvant chemotherapy. Within the group there 
were 32% patients with tumor size T1-T2, 49% of T3 pa-
tients and 13% females with advanced T4 tumor. No nodal 
metastases were found in 27% of patients (cN0), 42% of 
patients had N1 nodal involvement, 16% fixed/matted N2 
lymph node metastases and 15% advanced (N3) lymph node 
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involvement. Patients were subjected to initial chemother-
apy — the majority of patients (86%) received anthracy-
cline and taxane chemotherapy (56% received docetaxel/ 
/doxorubicin or epirubicin/cyclophosphamide — TAC/TEC 
regimen, 19% doxorubicin/docetaxel AT chemotherapy, 
11% sequential doxorubicin/cyclophosphamide-paclitaxel 
AC-P regimen), and 14% anthracycline-based regimen 
(5-fluorouracil/doxorubicin/cyclophosphamide, FAC). 42% 
of patients were hormone-sensitive and HER2-negative, 
20% hormone-sensitive HER2-positive, 9% non-luminal 
HER-positive and 29% with triple negative breast cancer. 
In total, 64% of the whole group showed hormone respon-
siveness (positive estrogen or progesterone staining on 
immunohistochemical staining, at least 1%) and in 29% 
of patients positive HER2 status was confirmed (either 
+++ in immunohistochemical staining or positive FISH 
in patients with ++ status).
Among the patients there were 9 individuals with meta-
static disease (M1) at initial presentation, and 11 patients 
were not treated surgically after initial chemotherapy (no 
sufficient disease response). 82 patients reached surgery, 
and the pathological complete response on postoperative 
examination was defined as the disappearance of invasive 
tumor both from tumor bed in breast and axillary lymph 
nodes. From 82 patients operated on, 20 patients (24%) 
showed pathological complete response (pCR), while in 
62 patients there was no pCR.
From all patients during pre-treatment core needle biopsy, 
upon the acceptance of Local Ethics Committee and after 
the patients’ informed consent the additional tissue material 
was collected and stored in RNAlater. RNA was isolated 
using RNeasy Mini kits including a digestion step with 
RNase-free DNase I (Qiagen), its quantity was measured 
spectrophotometrically (NanoDrop 1000 spectrophotome-
ter, Thermo Scientific), while the quality assessed by Agilent 
2100 Bioanalyzer and RNA 6000 Nano LabChip kit (Agilent 
Technologies). 
Four gene transcripts (MKI67, cyclin-dependent kinase 1 
[CDK1], heat shock proteins HSP90AA1 and HSP90AB1) 
were analyzed by quantitative real-time RT-PCR (QPCR) 
with fluorescent probes, by previously described methodo-
logy [3]. Amplicon design was achieved with Universal Probe 
Library (Roche). Reverse transcription was performed 
using Qiagen Omniscript RT Kit. The input RNA for each 
sample was 200 ng in a final volume of 20 μL. All samples 
were diluted 10 times prior to QPCR. Reactions were 
performed in duplicates on 384-well plates using 7900HT 
Fast Real-Time PCR system (Life Technologies). The 
QPCR conditions consisted of a first step at 50°C (2 min; 
activation and incubation with AmpErase UNG) and 95°C 
(10 min; activation AmpliTaq Gold polymerase), followed 
by 40 cycles of amplification (95°C, 15 s; 60°C, 1 min). Each 
reaction contained 10 μL of Taqman Universal Mastermix 
(Life Technologies), 200 nM of each primer, 2.8 μL RNase-
free water and 5 μL of diluted cDNA template. Standard 
curve was performed for each amplicon of the 8 duplicate 
concentrations (1000 ng, 500 ng, 200 ng, 100 ng, 40 ng, 20 ng, 
8 ng, and 2 ng of total RNA). The linear regression slope of 
the standard curve indicated amplification efficiency. For 
normalization of QPCR data five transcripts were chosen 
as reference: ACTB, GAPDH, GUSB, PRPLO, TFRC and 
the normalization factor was obtained using the geNorm 
applet for Microsoft Excel, based on the three reference 
genes tested. 
Results
Correlation of analyzed markers
Four genes were analyzed in the study — MKI67, 
well-established proliferation marker in breast can-
cer, cell-cycle related cyclin-dependent kinase 1, 
CDK1, and two HSP90 transcripts, HSP90AA1 and 
HSP90AB1. We assessed the pairwise correlations of 
four analyzed genes (see Figure 1). There was only 
a very weak correlation of MKI67 with CDK1 (R2 = 
0.042). MKI67 was not correlated with two investigat-
ed HSP90 transcripts. Instead, there was a moderate 
correlation between CDK1 and HSP90AA1 and 
AB1 transcripts (R2 = 0.37 and 0.35) and moderate 
correlation between both analyzed HSP90 transcripts 
(R2 = 0.29). 
Gene expression in relation to pCR status
For MKI67 transcript, mean expression in CR group 
was 0.74, in no CR group 0.65, ratio CR/no CR 1.14. 
Median values were 0.72 and 0.54, respectively, fold-
change CR/no CR 1.33 (see Figure 2A). The slight 
difference between CR and no CR groups was not 
significant (p = 0.099, U Mann-Whitney test).
For CDK1 transcript, there was almost no differ-
ence between CR and no CR groups (mean values 0.75 
and 0.72, medians 0.67 and 0.55, respectively, p = 0.35, 
U Mann-Whitney test, Figure 2B).
HSP90AA1 expression was significantly lower 
in patients with CR (mean: 0.76, 95% conf. interval 
0.59–0.93, median value 0.77) than in patients with no 
CR (mean: 1.02, 95% conf. interval 0.89–1.14, median 
value 0.87, p = 0.031, U Mann-Whitney test, Figure 2C). 
Fold-change CR/no CR for average values was 0.69, 
while for median values 0.89.
When the similar analysis was carried out for HSP-
90AB1, a trend was noted for lower expression in pa-
tients with CR (mean: 0.66, 95% conf. interval 0.48–0.83, 
median value 0.55) than in patients with no CR (mean: 
0.80, 95% conf. interval 0.70–0.89, median value 
0.74, p = 0.054, U Mann-Whitney test, Figure 2D). 
Fold change CR/no CR for average values was 0.82, 
while for median values 0.74.
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Figure 1. Pairwise correlation plots for all 4 analyzed transcripts (MKI67, CDK1, HSP90AA1, HSP90AB1). On both axes 
gene expression values are shown, with points representing individual patients. Regression lines are fitted, with 95% con-
fidence intervals (shaded). Much stronger correlations were observed between CDK1 and both HSP90 transcripts than 
between these three genes and MKI67.
Ratios of proliferation and HSP90 genes
We calculated the ratios of both proliferation genes 
analyzed (MKI67 and CDK1) to each of HSP90 tran-
scripts (AA1 and AB1), in total four pairwise combi-
nations. All four calculated ratios showed significant 
differences between CR and no CR groups, more 
pronounced when HSP90AA1 was involved (p = 0.002 
and p = 0.005 for CDK1 and MKI67 genes, respec-
tively), while slightly less prominent for HSP90AB1 
(p = 0.054 and p = 0.018 for CDK1 and MKI67, 
resp.) The most significant predictor of pCR was the 
ratio of CDK1 transcript to HSP90AA1 transcript. 
CDK1/HSP90AA1 ratio was significantly higher in CR 
group (mean 1.06, median 0.99) than in no CR group 
(mean 0.73, median 0.68, see Figure 3, p = 0.0023, 
U Mann-Whitney test). Fold change of average ratio 
values between CR and no CR was 1.45, very similar 
fold-change was observed for median values — 1.46.
Diagnostic utility
As the ratio of CDK1/HSP90AA1 showed significant 
differences between CR and no CR patients, we as-
sessed whether it could be used as a diagnostic test, 
by calculating the area under the receiver operating 
characteristic (ROC) curve. The area was 0.72 con-
firming the diagnostic utility of the CDK1/HSP90AA1 
ratio (see Figure 4). 
Discussion
The data obtained in our study suggest that the sensi-
tivity to chemotherapy in breast cancer is related more 
to the relationship between proliferation intensity 
(the higher, the more chemosensitive) and the tumor 
stress response (the higher, the more chemoresistant) 
than to each of the parameters alone. Only when both 
parameters were considered as a ratio, the differ-
ences between the tumors with pathological complete 
response and the more chemoresistant cancers were 
statistically significant. Ratio of CDK1 to HSP90AA1 
gene expression was better predictive of response to 
chemotherapy than proliferation rate measured by 
Ki67 transcript (MKI67). In fact, the majority of ob-
served discriminative power came from HSP90AA1/ 
/AB1 transcripts expression, not from MKI67/CDK1 
genes. 
One of the first studies to correlate heat shock 
proteins expression with chemosensitivity was the 
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Figure 2. Differences in gene expression in analyzed transcripts between patients with pathological complete response 
(CR) and no complete response (no CR). Box-and-whisker plots are shown in both groups. Gene expression values were 
compared by U Mann-Whitney test. For MKI67 and CDK1 transcripts the differences are not significant, p = 0.099 and 
p = 0.35, respectively. Difference in gene expression of HSP90AA1 significantly differentiated both groups (p = 0.031), 
while for HSP90AB1 it was of borderline significance (p = 0.054). 
Figure 3. Relative expression of CDK1 to HSP90AA1 gene 
(measured by the ratio of both gene expression values) be-
tween patients in CR and no CR groups. The difference is 
statistically significant, p = 0.0023, U Mann-Whitney test.
A B
C D
chemoresistance, although they were unable to iden-
tify any relation with immunohistochemically assessed 
proliferation rate.
HSP90 expression was first analyzed in breast can-
cer in 1999 [5], but until 2007 there was no systematic 
approach to associate it with clinical parameters. The 
negative impact of high HSP90 on patient survival 
was demonstrated by Pick et al. [6] by analysis of cell 
lines and patient-derived material in tissue microarray 
samples. High HSP90 protein staining was associat-
ed with shorter disease-free survival time, mainly in 
patients with early (node-negative) breast cancer. 
HSP90 was associated with disease-free survival 
time also when considered in the context of tumor 
size, steroid receptors and HER2 expression. High 
HSP90 expression was strongly associated with high 
nuclear grade, positive HER2 staining, larger tumor 
size, steroid receptors and lymph node metastases. 
Significant acceleration in the understanding of 
HSP90 role in breast cancer has been achieved by 
analysis of multiple microarray datasets. This has been 
addressed by Cheng et al. [7] by compiling of more 
analysis by Vargas-Roig et al. [4]. Authors analyzed 
the levels of Hsp70 and Hsp27 proteins and observed 
some association of high expression with tumor 
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Figure 4. Diagnostic utility of CDK1/HSP90AA1 ratio to 
differentiate between CR and no CR patients, assessed by 
receiver operating characteristic (ROC) curve. The area 
under ROC curve was 0.72, confirming the diagnostic  
utility of the CDK1/HSP90AA1. 
than 4 thousand of samples from more than 20 datasets. 
The authors found that HSP90AA1 was associated with 
risk of death in triple-negative breast cancer, while 
HSP90AB1 was highly associated with risk of death in 
hormone-receptor positive breast cancer. Both genes 
were significantly associated with disease-free and 
overall survival in the whole cohort of patients. 
Authors used also The Cancer Genome Atlas 
data [8] to demonstrate that the increased expression 
of each of HSP90 transcripts (cytoplasmic isoforms 
HSP90AA1 and AB1) might be driven either by am-
plifications of these genes or amplification of HSF1 
transcription factor gene. When authors considered 
all reasons of activation of HSP90 gene (including 
HSF1 amplification) and analyzed its association with 
survival in all samples from 23 datasets gathered in the 
study, this upregulation was associated with the risk of 
death, especially in estrogen-receptor positive cancer. 
The largest effect was seen on the risk of recurrence 
in triple negative breast cancer.
Taking into account the potentially increased 
aggressiveness, related to high HSP expression, the 
use of HSP inhibition seem to be the rational option 
of novel anti-cancer therapy. This concept has been 
evaluated in many cancers [9–16], including numer-
ous attempts in pre-clinical and clinical breast cancer 
models [17–27] (reviewed in [28]).
However, HSP is probably not acting alone in deter-
mination of breast cancer aggressiveness. Song et al. [29] 
analyzed by immunohistochemistry the effect of 
HSP90 expression on breast cancer relapse risk and 
found that increased HSP90 expression is significantly 
associated with its shortening. They noted that this 
effect is particularly pronounced in cases with PTEN 
loss or PI3K overexpression and that this interaction 
is clear in HER2 positive cases. Nevertheless, also in 
triple negative patients or luminal B subtype there 
was also a trend for worse prognosis related to higher 
HSP90 expression. TOPO2–HSP90 complex has also 
been indicated by Barker et al. as a potential valuable 
chemotherapeutic target [30].
Obviously, not only HSP90 was studied in the 
context of chemoresponsiveness. Important obser-
vations indicating that other heat shock proteins also 
play a role were published for HSP70 [31] and HSP27 
[32–34]. The association of HSP90 gene expression 
with different pathological and clinical features of 
breast cancer has not yet been studied extensively in 
the novel setting of molecular subtypes of this disease. 
However, additionally to the suggestions that the role 
may be particularly associated with HER2-positive 
disease, there were also observations that HSP90 
exhibits low expression in the lobular histotype [35]. 
In summary, HSP90 has been linked to chemore-
sistance in different clinical settings including breast 
cancer [36–41].The described study of Song et al. [29] 
corroborates the observations that low HSP90 expres-
sion is a positive prognostic feature. In our study we 
pinpointed the predictive aspect of the association 
of HSP90 with proliferation markers and its asso-
ciation with the higher response to chemotherapy. 
HSP90AA1 and AB1 genes exhibit low expression in 
breast cancers highly sensitive to chemotherapy and 
may indicate the patients with higher probability of 
pathological complete response. High HSP90 gene 
expression may be one of the mechanisms driving 
chemoresistance or might be a part of tumor aggres-
sive phenotype. The ratio of HSP90AA1 to prolifera-
tion-related markers (CDK1 or MKI67) may be even 
better predictor of pCR chance, with higher expres-
sion of proliferation genes and lower stress response 
in patients sensitive to chemotherapy.
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